Susquehanna International Group
BTAI icon

Susquehanna International Group’s BioXcel Therapeutics BTAI Stock Holding History

Susquehanna International Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,025
Closed -$103K – 12028
2024
Q2 		$103K Buy
5,025
+456
+10% +$15.3K ﹤0.01% 11013
2024
Q1 		$206K Buy
4,569
+3,100
+211% +$148K ﹤0.01% 10539
2023
Q4 		$69.3K Sell
1,469
-19,387
-93% -$1.08M ﹤0.01% 11552
2023
Q3 		$844K Buy
20,856
+18,112
+660% +$1.83M ﹤0.01% 7021
2023
Q2 		$292K Sell
2,744
-3,825
-58% -$1.27M ﹤0.01% 9492
2023
Q1 		$1.96M Buy
6,569
+4,313
+191% +$1.84M ﹤0.01% 5196
2022
Q4 		$775K Sell
2,256
-400
-15% -$96.7K ﹤0.01% 6744
2022
Q3 		$502K Buy
2,656
+1,081
+69% +$251K ﹤0.01% 8476
2022
Q2 		$333K Sell
1,575
-2,981
-65% -$627K ﹤0.01% 9290
2022
Q1 		$1.52M Buy
4,556
+2,112
+86% +$612K ﹤0.01% 6096
2021
Q4 		$795K Sell
2,444
-5,712
-70% -$2.45M ﹤0.01% 7903
2021
Q3 		$3.96M Buy
8,156
+1,768
+28% +$777K ﹤0.01% 4385
2021
Q2 		$2.97M Buy
6,388
+4,032
+171% +$2.2M ﹤0.01% 5045
2021
Q1 		$1.63M Sell
2,356
-7,600
-76% -$6.11M ﹤0.01% 6428
2020
Q4 		$7.36M Buy
9,956
+3,650
+58% +$2.84M ﹤0.01% 2878
2020
Q3 		$4.38M Sell
6,306
-6,244
-50% -$4.69M ﹤0.01% 3237
2020
Q2 		$10.6M Buy
12,550
+9,250
+280% +$6.03M ﹤0.01% 2059
2020
Q1 		$1.18M Buy
+3,300
New +$1.19M ﹤0.01% 5019

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's BTAI Position: Q1 2025 in Review

Susquehanna International Group sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,158 shares — an estimated $12.9K sold.

Susquehanna International Group first reported a position in BTAI in Q2 2020 and held it in 18 quarters. The position peaked at $9.99M in Q3 2020. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Susquehanna International Group reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 2,158 BioXcel Therapeutics shares in Q1 2025, an estimated $12.9K.
  • Susquehanna International Group first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 18 quarters.
  • Susquehanna International Group's BioXcel Therapeutics position peaked at $9.99M in Q3 2020.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.